Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    Special Populations
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    March 10, 2023
    How I Practice Mindfulness as an Oncology Nurse
    Nurse well-being
    How I Practice Mindfulness as an Oncology Nurse
    March 03, 2023
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

    On March 11, 2022, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza®) for adult patients with deleterious or suspected deleterious germline BRCA variant (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients are selected for therapy based on an FDA-approved companion diagnostic for olaparib.

    March 18, 2022
    FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

    On February 28, 2022, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti™) for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. Ciltacabtagene autoleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy.

    March 18, 2022
    FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage Non-Small Cell Lung Cancer

    On March 4, 2022, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting, representing the first FDA approval for neoadjuvant therapy for early-stage NSCLC.

    March 18, 2022
    FDA Reports Recall of 0.9% Sodium Chloride for Injection USP 250 ml in Excel Because of Fluid Leakage or Low Fill Volume
    U.S. Food and Drug Administration (FDA)

    FDA Reports Recall of 0.9% Sodium Chloride for Injection USP 250 ml in Excel Because of Fluid Leakage or Low Fill Volume

    On March 3, 2022, the U.S. Food and Drug Administration (FDA) reported B. Braun Medical’s voluntary recall of five lots of 0.9% sodium chloride for injection USP 250 ml in Excel within the United States at the hospital and user levels after receiving reports of fluid leakage or low fill volumes.

    March 14, 2022
    Mama at the Bar: Using Analogies to Understand Targeted Therapies
    Nursing education

    Mama at the Bar: Using Analogies to Understand Targeted Therapies

    Analogies and visuals are powerful learning tools. If you’re one of the many nurses whose eyes glaze over when approaching genomics, consider connecting the “omics” concepts to interpretative visuals, clinical practice, and everyday life examples to enhance your learning and make the concepts more relevant to you. Here’s an example of how it can be done.

    March 10, 2022
    Nursing Considerations for ICI-Related Myocarditis
    Cancer research

    Nursing Considerations for ICI-Related Myocarditis

    Before immunotherapies like immune checkpoint inhibitors (ICIs) became a cancer treatment option, myocarditis typically developed in the presence of infections, drug allergies, or autoimmune diseases. Activating the immune system with ICIs can also trigger autoimmune-like adverse events such as myocarditis, and although its incidence in patients with cancer is low, mortality is high.

    March 08, 2022
    Prevent Implicit Bias in Patient Care With These Cultural Conversation Starters
    Cultural/ethnic issues

    Prevent Implicit Bias in Patient Care With These Cultural Conversation Starters

    Each clinical encounter with a patient brings together three different cultural perspectives: the patient’s, the nurse’s, and health care’s own culture. Patient-centered care acknowledges and responds to the unique needs and preferences of each patient in the context of their culture. As we approach our patients with respect, humility, and curiosity to learn more, we must ask questions to help prevent assumptions, generalizations, and implicit bias from influencing our interactions.

    March 03, 2022
    FDA Reports Safety Announcement for Spectrum V8 and Spectrum IQ Infusion Pumps
    U.S. Food and Drug Administration (FDA)

    FDA Reports Safety Announcement for Spectrum V8 and Spectrum IQ Infusion Pumps

    On February 18, 2022, the U.S. Food and Drug Administration (FDA) reported Baxter International’s urgent safety communication to reinforce safety information regarding upstream occlusion alarms for all Spectrum V8 and Spectrum IQ infusion pumps.

    February 24, 2022
    Music Reminds You of the Love You Deserve
    Nurse well-being

    Music Reminds You of the Love You Deserve

    Does hearing a certain song suddenly energize you or make the day seem brighter? There’s a reason for that. Music can have a powerful effect on our well-being and is a tool nurses can use to help take care of their mental health.

    February 24, 2022
    Immune Checkpoint Inhibitors May Increase Risk of Serious Infection
    Cancer research

    Immune Checkpoint Inhibitors May Increase Risk of Serious Infection

    Nearly a quarter of patients receiving a variety of drugs classified as immune checkpoint inhibitors develop infections during treatment and 15% are considered severe, researcher reported in study findings published in Cancer Medicine.

    February 23, 2022
    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv

    In clinical trials, 24% of patients achieved an objective response rate with tisotumab vedotin-tftv (TivdakTM) that lasted a median of 8.3 months, leading to the agent’s U.S. Food and Drug Administration September 2021 approval for use in adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

    February 22, 2022
    Master the Essentials of Effective Communication
    Oncology nurse-patient relationship

    Master the Essentials of Effective Communication

    Communication is central to an oncology nurse’s role—with patients and families, within the unit, and across interprofessional teams. The Joint Commission identified poor communication as a causative factor in 80% of medical errors, particularly during caregiving handoffs. Effective communication skills are both a science and an art, but oncology professionals can use a variety of tools and techniques to enhance their practice.

    February 15, 2022
    COVID-19’s Impact on Our Nursing Leaders
    COVID-19

    COVID-19’s Impact on Our Nursing Leaders

    Rewind. I adjust the strap on my mask and pinch it tightly around my nose and move it just under my lower eyelashes to prevent my goggles from fogging. These days, I am grateful for the face cover as it hides the pallor from six months in and the dark circles from long hours and anxious sleep. I wait at the valet circle for my team. Another SOS text out to them this morning. All hands on deck.

    February 14, 2022
    Geriatric Assessments Reduce Side Effect Incidence in Older Adults With Cancer
    Cancer research

    Geriatric Assessments Reduce Side Effect Incidence in Older Adults With Cancer

    Regularly conducting geriatric assessments in older patients and using the information to guide their care reduces their risk of side effects by nearly 30%, researchers reported in study findings published in Lancet.

    February 09, 2022
    Evidence Defines Nursing Implications for Combination Cancer Treatment Side Effects
    Combination therapy

    Evidence Defines Nursing Implications for Combination Cancer Treatment Side Effects

    Immune checkpoint inhibitors (ICIs) enhance immune response against foreign antigens, such as cancer, by manipulating checkpoints that have stopped the body from fighting them. In doing so, they also increase risk of the immune system attacking healthy cells and producing inflammatory side effects, resulting in immune-related adverse events (irAEs).

    February 08, 2022
    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
    Cancer research

    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer

    Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.

    February 02, 2022
    The Pharmacist’s Role in Combination Cancer Treatments
    Combination therapy

    The Pharmacist’s Role in Combination Cancer Treatments

    Since the first checkpoint inhibitor was approved in 2011, we have made tremendous leaps in immunotherapy in a short span of 10 years. Now we see immunotherapy combined with a variety of options, including chemotherapy or other oral and IV targeted therapy.

    February 01, 2022
    What the Evidence Says About Traditional Chinese Medicine Herbal Formula Xiao Yao San for Depression and Anxiety
    Complementary therapy

    What the Evidence Says About Traditional Chinese Medicine Herbal Formula Xiao Yao San for Depression and Anxiety

    An estimated 16% of patients with cancer experience depressive spectrum disorders in oncologic, hematologic, and palliative care settings, seriously affecting their quality of life. Although conventional antidepressants can be effective in many situations, they are associated with adverse effects, such as fatigue, drowsiness, sleep difficulties, nausea, weight gain, nervousness, dry mouth, blurred vision and sexual dysfunction.

    January 28, 2022
    Oncology Drug Reference Sheet: Ivosidenib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Ivosidenib

    Adding to its earlier approvals for use in adults with acute myeloid leukemia (AML), on August 25, 2021, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo®) for adults with previously treated, locally advanced or metastatic cholangiocarcinoma. Cholangiocarcinoma, or cancer of the bile ducts, is a rare cancer, and ivosidenib is the only currently approved agent for patients with an IDH1 variant.

    January 25, 2022
    Cancer Cells’ Aneuploidy May Be Why They Resist Treatment
    Cancer research

    Cancer Cells’ Aneuploidy May Be Why They Resist Treatment

    The extra or missing chromosomes—also called aneuploidy—in 90% of cancer cells may be a factor in treatment resistance, a new study shows. Researchers reported the findings in Developmental Cell.

    January 19, 2022
    Genetic Disorder Reference Sheet: CDH1 and Hereditary Diffuse Gastric Cancer
    Genetics & genomics

    Genetic Disorder Reference Sheet: CDH1 and Hereditary Diffuse Gastric Cancer

    Pathogenic variants in the CDH1 gene are associated with hereditary diffuse gastric cancer (HDGC), a poorly differentiated adenocarcinoma that infiltrates into the stomach wall. It causes the stomach wall to thicken without forming a distinct mass, which limits effective screening strategies.

    January 18, 2022
    The Case of the Post-Transplant Pulmonary Problem
    Clinical practice

    The Case of the Post-Transplant Pulmonary Problem

    Benjamin, your 28-year-old patient with acute lymphoblastic leukemia, received a 10/10 matched, unrelated donor for his allogeneic hematopoietic stem cell transplantation. Two months post-transplant, Benjamin developed grade 4 skin and gastrointestinal graft-versus-host disease. 

    January 14, 2022
    Break Bad News to Patients With This Step-by-Step Guide
    Advanced Practice Nursing (APRN)

    Break Bad News to Patients With This Step-by-Step Guide

    When hearing results from blood work or repeat imaging—regardless of whether they are “good” or “bad”—patients want and deserve to be given information truthfully and objectively. Oncology advanced practice providers are often the bearers of bad news, which can be uncomfortable and stressful. But here’s how you can hold those conversations with finesse, empathy, and respect.

    January 13, 2022
    Team Training Develops Nurses’ Interprofessional Communication Skills
    Interprofessional issues

    Team Training Develops Nurses’ Interprofessional Communication Skills

    Oncology nurses must have effective communication and team-based skills to work across disciplines with other members of the care team. In an oncology setting, teamwork promotes safer, more efficient, and higher quality care, as well as a more positive and supportive practice environment. Dana-Farber Cancer Institute (DFCI) has used team training to develop those skills in our staff over the past 15 years.

    January 11, 2022
    Train and Retain: From Orientation to Leadership, Here Are the Strategies That Experienced Staff Developers Use
    Nurse staffing

    Train and Retain: From Orientation to Leadership, Here Are the Strategies That Experienced Staff Developers Use

    The oncology nursing specialty is in dire need of a solid foundation of eligible staff. As of 2020, more than 51% of the nursing workforce was aged 40 years or older, and the COVID-19 pandemic exacerbated underlying factors such as stress, physical and mental health, and inequities present in the profession for decades.

    January 11, 2022
    Bolster Your Team for Better Well-Being
    Nurse well-being

    Bolster Your Team for Better Well-Being

    Nurse burnout can only be addressed at the health system level, and beginning in your unit is one way to get that process started.

    January 06, 2022
    Mental Health Teams Build Programs That Prioritize Staff Well-Being
    Nurse well-being

    Mental Health Teams Build Programs That Prioritize Staff Well-Being

    Given the inherent nature of caregiving, burnout has been part of the nursing profession since the beginning. As the complexities of the profession increase, so do nurses’ vulnerability. Oncology nurses have multiple physical, emotional, and mental demands, which, if left unaddressed, can lead to burnout, compassion fatigue, and moral distress.

    January 04, 2022
    Make Subcutaneous Administration More Comfortable for Your Patients
    Clinical practice

    Make Subcutaneous Administration More Comfortable for Your Patients

    Much of oncology nursing education focuses on IV administration of systemic therapies because for years, that was the only route. Until 2004, only two cancer therapies were approved for subcutaneous (SC) administration, and just nine others were added through 2012. However, as more familiar IV therapies get SC counterparts, including the more recent approvals of four high-volume monoclonal antibodies (mAbs), infusion nurses are using them more regularly in practice.

    January 04, 2022
    Show the World Your Beautiful Mess
    Nurse well-being

    Show the World Your Beautiful Mess

    Embracing—not judging or hiding—our flaws and vulnerabilities makes us happier and more relatable, a research-supported concept called the beautiful mess effect. What we think are negatives or weaknesses, others see as courageous. Showing vulnerability can lead to stronger relationships, increased self-esteem, and better mental health.

    December 30, 2021
    Liver Cancer Diagnoses See Geographic, Racial, Income Disparities
    Cancer health disparities

    Liver Cancer Diagnoses See Geographic, Racial, Income Disparities

    The urban-rural disparity in hepatocellular cancer (HCC) diagnoses is widening, researchers said, particularly in certain racial, income, and age groups. The authors reported their study results in Clinical Gastroenterology and Hepatology.

    December 29, 2021
    Oncology Drug Reference Sheet: Amivantamab-Vmjw
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Amivantamab-Vmjw

    After clinical trials demonstrated a 40% overall response rate with 63% of responses lasting six months or more, on May 21, 2021, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (RybrevantTM) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion variants, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

    December 28, 2021
    Oncology Nurses Share Successes and Challenges Adapting to Telehealth During COVID-19
    COVID-19

    Oncology Nurses Share Successes and Challenges Adapting to Telehealth During COVID-19

    The COVID-19 coronavirus pandemic has forced healthcare providers to make unprecedented adjustments to patient care, including the pivot to telehealth. At a series of virtual events from October 2020–March 2021, ONS members shared their challenges, successes, and future needs to permanently adopt virtual cancer care visits.

    December 24, 2021
    The Case of the Clinical Trials Consultation
    Oncology clinical trials

    The Case of the Clinical Trials Consultation

    Don, age 72, was diagnosed with borderline resectable pancreatic adenocarcinoma more than a year ago. Genetic testing indicated a BRCA2 variant. He completed 12 cycles of FOLFIRINOX followed by a pancreaticoduodenectomy (Whipple procedure). He had no evidence of disease for six months until a liver lesion seen on surveillance imaging tested positive for metastatic pancreatic cancer. His medical oncologist suggests a clinical trial targeting the BRCA2 variant.

    December 21, 2021
    FDA Approves Abatacept for Prophylaxis of Acute Graft-Versus-Host Disease
    U.S. Food and Drug Administration (FDA)

    FDA Approves Abatacept for Prophylaxis of Acute Graft-Versus-Host Disease

    On December 15, 2021, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia®) for prophylaxis of acute graft-versus-host disease (aGVHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and pediatric patients aged 2 and older who are undergoing hematopoietic stem cell transplantation (HSCT) from a matched or one allele-mismatched unrelated donor.

    December 16, 2021
    Traits That Make You  a Great Nurse Also Lead to Success as a Clinical Trials PI
    Oncology clinical trials

    Traits That Make You a Great Nurse Also Lead to Success as a Clinical Trials PI

    Clinical trials are led by a principal investigator (PI) with a research team that may include physicians, nurses, social workers, and other healthcare professionals. PIs can represent a variety of disciplines, and nurse scientists often hold that role.

    December 14, 2021
    Nursing Considerations for Adolescent and Young Adult Cancer Survivorship Care
    Survivorship

    Nursing Considerations for Adolescent and Young Adult Cancer Survivorship Care

    Adolescent and young adults (AYAs)—those diagnosed between the ages of 15 and 39—comprise about 5% of all annual cancer diagnoses. The population has unique challenges that must be considered as part of patient-centered survivorship care planning.

    December 13, 2021
    Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients
    Oncology clinical trials

    Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients

    Among the many online resources for identifying cancer clinical trials, including the National Cancer Institute (NCI), NCI-designated cancer centers or academic cancer centers, and drug and biotechnology companies, ClinicalTrials.gov may be the most comprehensive as a one-stop shop for patients and providers to find publicly and privately supported trials for patients.

    December 09, 2021
    FDA Reports Teligent Pharma’s Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4%
    U.S. Food and Drug Administration (FDA)

    FDA Reports Teligent Pharma’s Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4%

    On December 7, 2021, the U.S. Food and Drug Administration (FDA) reported Teligent Pharma’s voluntary recall of two lots of lidocaine HCl topical solution 4% in a 50 ml screw cap glass bottle to the user level. The manufacturer’s testing found that the product is super potent based on an out-of-specification result at the 9-month (lot 16345) and 18-month (lot 15594) stability timepoint.

    December 08, 2021
    Patients Cope With Intense Emotions After Clinical Trial Withdrawal
    Oncology clinical trials

    Patients Cope With Intense Emotions After Clinical Trial Withdrawal

    When withdrawing from a clinical trial, patients experience a spectrum of emotions ranging from regret, urgency, frustration—and trust in their healthcare professionals, like oncology nurses, according to the results of a study published in JAMA Network Open.

    December 08, 2021
    Nursing Roles in Clinical Trials
    Oncology nursing roles

    Nursing Roles in Clinical Trials

    Clinical trials provide evidence to support what you do in your work as a nurse every day. They are tools to discover new therapies and identify side effects while considering patient-specific factors like age, comorbidities, race, and sex. They build support for best practices in treatment and patient care.

    December 07, 2021
    CMS, HHS Issue Emergency Regulation Requiring COVID-19 Vaccination for Healthcare Workers
    COVID-19

    CMS, HHS Issue Emergency Regulation Requiring COVID-19 Vaccination for Healthcare Workers

    In an effort to protect patients and control the COVID-19 coronavirus pandemic, the Centers for Medicare and Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS) have issued an interim final rule requiring all staff at certain Medicare- and Medicaid-certified healthcare facilities to be vaccinated against COVID-19.

    December 01, 2021
    FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumor
    U.S. Food and Drug Administration (FDA)

    FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumor

    On November 22, 2021, the U.S. Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (Fyarro™) for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

    November 23, 2021
    Oncology Drug Reference Sheet: Sotorasib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Sotorasib

    After clinical trials demonstrated an overall response rate of 36% and median response duration of 10 months, the U.S. Food and Drug Administration granted sotorasib (LumakrasTM) accelerated approval on May 28, 2021, for the treatment of adults with KRAS G12C–altered locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

    November 23, 2021
    New NIH Program Aims to Increase Gene Therapies for Rare Diseases
    Cancer research

    New NIH Program Aims to Increase Gene Therapies for Rare Diseases

    To accelerate the development of gene therapies for the 30 million Americans who have been diagnosed with a rare disease, in October 2021 the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), 10 pharmaceutical companies, and five nonprofit organizations announced the creation of the Bespoke Gene Therapy Consortium (BGTC). The consortium is optimizing and streamlining the gene therapy development process to help fill the unmet medical needs of people with rare diseases.

    November 18, 2021
    FDA Permits Marketing of E-Cigarette Products, Marking First Authorization of Its Kind
    U.S. Food and Drug Administration (FDA)

    FDA Permits Marketing of E-Cigarette Products, Marking First Authorization of Its Kind

    Under the authority given in the Family Smoking Prevention and Tobacco Control Act, in October 2021 the U.S. Food and Drug Administration (FDA) authorized the marketing of three new electronic nicotine delivery system (ENDS) products, “marking the first set of ENDS products ever to be authorized by FDA through the Premarket Tobacco Product Application pathway.” The agency made the announcement it continues its review of thousands of tobacco and e-cigarette products’ marketing applications.

    November 17, 2021
    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance
    Cancer research

    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance

    Novobiocin, an antibiotic discovered during the 1950s, may be a potential second-line therapy for patients whose tumors have become resistant to poly (ADP-ribose) polymerase (PARP) inhibitors, researchers reported in Nature Cancer. The finding may open up new options for patients with BRCA-variant disease such as breast, ovarian, pancreatic, and prostate cancer.

    November 17, 2021
    Defining Individual Biosignatures Through Precision Health Symptom Science Helps Nurses Deliver Even Better Care
    Symptom management

    Defining Individual Biosignatures Through Precision Health Symptom Science Helps Nurses Deliver Even Better Care

    Understanding the underlying mechanisms of cancer­related symptoms enables oncology nurses to provide the best patient-centered care. Biosignatures are indicators of life, and in disease, they contribute to the determination of clinical profiles. Identifying specific biologic markers associated with similar patient characteristics and symptoms may help us create tailored interventions for improved symptom management.

    November 16, 2021
    FDA Reports Recall of Custom Convenience Kits Because of Prefilled Syringe Plunger Defect
    U.S. Food and Drug Administration (FDA)

    FDA Reports Recall of Custom Convenience Kits Because of Prefilled Syringe Plunger Defect

    On November 9, 2021, the U.S. Food and Drug Administration (FDA) reported Aligned Medical Solutions’ recall of its custom convenience kits because of the potential for the plunger of the Cardinal Health monoject flush prefilled syringe (0.9% sodium chloride) to draw back after the air has been expelled and reintroduce air back into the syringe. FDA identified the recall as a class I recall, the most serious type of recall.

    November 12, 2021
    APRNs Can Lead by Example When Integrating Palliative Care in Practice
    Palliative care

    APRNs Can Lead by Example When Integrating Palliative Care in Practice

    Early and regular integration of palliative care (PC) improves patient and caregiver outcomes in symptom management, quality of life, psychosocial health, communication, shared decision-making, overall satisfaction—and even survival. Health systems also benefit through reduced emergency department visits, hospitalizations, and intensive care stays; increased completion of advanced directives; and improved quality of end-of-life care. Both the Centers for Medicare and Medicaid Services’ (CMS’s) Oncology Care Model and many oncology organizations, including ONS, support the approach for patients with cancer.

    November 11, 2021
    Genetic Disorder Reference Sheet: Familial Adenomatous Polyposis
    Genetics & genomics

    Genetic Disorder Reference Sheet: Familial Adenomatous Polyposis

    Individuals with 10–100+ polyps may have a germline pathogenic variant in the APC gene, placing them at higher risk for developing colorectal, gastrointestinal, and other cancers. The condition is known as familial adenosis polyposis (FAP), and loss of function in the APC gene is the first step in the adenoma-to-carcinoma sequence. Some people have an attenuated form (aFAP), with delayed polyp growth and fewer polyps (see sidebar). As many as 20% are de novo, meaning that they are the first in their family to have an identified pathogenic variant.

    November 04, 2021
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲